Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.

R Ramphal; M Bolger; D J Oblon; R J Sherertz; J D Malone; K H Rand; M Gilliom; J W Shands; B S Kramer

doi:10.1128/AAC.36.5.1062

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.

Identifier:nobleid.org/w1/20260515/DAEC2DC5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DAEC2DC5.svg?ark=w1%2F20260515%2FDAEC2DC5)](https://nobleid.org/work/w1/20260515/DAEC2DC5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.

Identifier:nobleid.org/w1/20260515/DAEC2DC5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DAEC2DC5.svg?ark=w1%2F20260515%2FDAEC2DC5)](https://nobleid.org/work/w1/20260515/DAEC2DC5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work